NEW YORK, NY--(Marketwired - Mar 15, 2014) - In the news release, "Faruqi & Faruqi, LLP
Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In
The Medicines Company To Contact The Firm," issued earlier today, please be
advised that the source company should be Faruqi & Faruqi, LLP instead of
The Medicines Company as originally issued incorrectly by Marketwired.
Complete corrected text follows.
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of
$100,000 Investing In The Medicines Company To Contact The Firm
NEW YORK, NY -- March 15, 2014 -- Faruqi & Faruqi, LLP, a leading national
securities law firm, reminds investors in The Medicines Company
("Medicines" or the "Company") (NASDAQ: MDCO) of the April 22, 2014
deadline to seek the role of lead plaintiff in a federal securities class
action lawsuit filed against Medicines and certain executives.
A complaint has been filed on behalf of all persons who purchased or
otherwise acquired Medicines securities between February 20, 2013 and
February 12, 2014, inclusive (the "Class Period") in the District of New
The complaint alleges that the Company and its executives violated federal
securities laws with respect to its disclosures concerning its business,
operations, and prospects.
Specifically, the action alleges that throughout the Class Period
defendants made false and/or misleading statements and/or failed to
disclose that: (i) the Company's drug candidate, Cangrelor, did not show
superiority when compared to clopidogrel, a competing drug previously
approved by the FDA; and (ii) the Company's CHAMPION clinical trials
comparing Cangrelor's efficacy with that of clopidorel were unethical and
On February 12, 2014, the Company announced that the NASDAQ had halted the
trading of its stock in connection with an FDA advisory panel. Later that
same day, the FDA advisory panel voted against approval of Cangrelor.
Following this news, the Company's stock declined $3.82 per share, or over
11%, to close at $29.28 per share on February 13, 2014.
Request more information now by clicking here: www.faruqilaw.com/MDCO.
There is no cost or obligation to you.
If you invested in Medicines stock, bonds or options between February 20,
2013 and February 12, 2014 and would like to discuss your legal rights,
visit www.faruqilaw.com/MDCO. You can also contact us by calling Richard
Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330
or by sending an e-mail to firstname.lastname@example.org or
email@example.com. Faruqi & Faruqi, LLP also encourages anyone with
information regarding Medicines' conduct to contact the firm, including
whistleblowers, former employees, shareholders and others.
Faruqi & Faruqi, LLP is a national law firm which represents investors and
individuals in class action litigation. The firm is focused on providing
exemplary legal services in complex litigation in the areas of securities,
shareholder, antitrust and consumer litigation, throughout all phases of
litigation. The firm has an experienced trial team which has achieved
significant victories on behalf of the firm's clients. To keep track of the
latest securities litigation news, follow us on Twitter at
www.twitter.com/MergerActivity or on Facebook at
Attorney Advertising. The law firm responsible for this advertisement is
Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or
predict a similar outcome with respect to any future matter. We welcome the
opportunity to discuss your particular case. All communications will be
treated in a confidential manner.